Plain-English translation of NCT05620940 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing two new injectable medications — and — that are being developed to treat opioid and alcohol dependence. Researchers want to understand how the body absorbs, processes, and eliminates these medications, and to compare them with Vivitrol (an existing FDA-approved long-acting injectable naltrexone treatment). The study involves healthy adult volunteers who will receive single injections and be carefully monitored.
Before these medications can be tested in patients with opioid or alcohol dependence, researchers need to understand how they work in healthy people first — how long they stay in the body, how safe they are, and whether they cause any side effects. This early testing helps determine the right doses to use in future studies.
You likely qualify if…
You likely don't qualify if…
You will receive a single injection (either into a muscle or under the skin, depending on which group you're assigned to) of either the new medication or the comparison treatment. You will then stay at the clinical research site where researchers will take blood samples at various time points to measure how your body processes the medication. The study is designed as a single dose, so you won't need to return for multiple drug administrations, though you may have follow-up visits for safety checks.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Australia
Phase
Safety & dosing
Sponsor
Inventage Lab., Inc.
Enrollment target
~40 participants
Started
September 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 55 Years
Sex
Male only
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
HyeRyeon Kim
Inventage Lab., Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.